Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal that may be presented to ...
Novavax said on Tuesday it has entered into a licensing agreement with Pfizer to develop vaccine products for infectious ...
Sun Pharma is weighing the acquisition of US-based Organon in a deal valued at about $10 billion, a move that would ...
Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s ...
A full professor of markets, organisations and society at UCD, Prof Geiger is a leading international expert on ...
English alphabets can't be trademarked: Delhi HC rejects pharma firm's plea to protect "A TO Z" mark
The Delhi High Court recently held that English alphabets cannot be monopolised through trademark law and refused interim ...
Commenting on the project, Hamid bin Saif al Sabahi, Founder and Executive Director of Adawaa Al Wataniya Pharmaceutical ...
ACA Pharma: [email protected] Azurity Pharmaceuticals: [email protected] ...
The "A Practical Approach to Developing the CMC Package for Veterinary Pharmaceutical Products Training Course (May 7, 2026)" has been added to ResearchAndMarkets.com's offering. Understanding the ...
THE Tanzanian government has begun implementing its agenda to establish and strengthen pharmaceutical and medical devices ...
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and marketed in Japan as QUVIVIQ®Phase 3 trial of ...
LISLE, IL, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- OWP Pharmaceuticals today announced commercial product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback